Butterfly Network (BFLY) exploded 56% in a single session last week after AI imaging company Midjourney announced the launch of Midjourney Medical — a new healthcare division paired with a prototype full-body ultrasound scanner called the Midjourney Scanner. Each unit incorporates 40 of Butterfly’s proprietary Ultrasound-on-Chip modules. Midjourney’s stated ambition: deploy 5,000 “Midjourney Spas” and 50,000 scanners globally by 2031. For a company with a market cap of roughly $1.4 billion, that represents a potential supply relationship of transformative scale — and the market priced in a significant chunk of that potential in a single trading day.
What makes the Butterfly Network situation particularly notable is that two independent analysts, using completely different methodologies, identified the stock simultaneously. One spotted BFLY breaking out of a three-year basing pattern using stage analysis — a framework focused purely on price structure, with all three major moving averages turning higher. A second analyst identified the same name based on fundamental research into the Midjourney Medical partnership pipeline. Two different methods, same stock, same week. That kind of independent confirmation is a strong signal in markets where noise typically drowns out signal. The Ultrasound-on-Chip technology is the key differentiator: Butterfly has miniaturized ultrasound — traditionally requiring large hospital-grade machines — into a semiconductor chip that enables handheld and body-scanner form factors at dramatically lower cost.
For retail investors, the 56% pop has already happened. But the question is whether this is the beginning of a larger re-rating. If Midjourney follows through on even a fraction of its 50,000-scanner deployment target, Butterfly’s annual revenue could multiply several times from current levels. The stock has pulled back modestly from its weekly high on profit-taking — which historically creates better entry conditions for investors who missed the initial move. The risk is execution: Midjourney Medical is pre-revenue, and hardware deployment at scale is notoriously slow. But with AI healthcare spending accelerating rapidly and few pure-play ultrasound chip companies publicly traded, Butterfly Network sits at a unique intersection of AI, medical devices, and mass-market diagnostics that retail investors should keep on their watchlist.
